Which has higher earnings and valuation, MED or VERU?

Medifast has higher revenue and earnings than Veru. Medifast is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medifast $385.79M 0.34 -$18.67M -$1.83 N/A Veru $16.89M 2.85 -$22.73M -$0.89 N/A

Is MED or VERU more profitable?

Veru has a net margin of 0.00% compared to Medifast's net margin of -5.78%. Medifast's return on equity of -4.80% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Medifast -5.78% -4.80% -3.83% Veru N/A -54.72% -39.09%

Does the media prefer MED or VERU?

In the previous week, Medifast and Medifast both had 3 articles in the media. Veru's average media sentiment score of 0.43 beat Medifast's score of 0.22 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VERU or EL?

In the previous week, Estee Lauder Companies had 14 more articles in the media than Veru. MarketBeat recorded 17 mentions for Estee Lauder Companies and 3 mentions for Veru. Estee Lauder Companies' average media sentiment score of 1.08 beat Veru's score of 0.43 indicating that Estee Lauder Companies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estee Lauder Companies 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, VERU or IPAR?

Interparfums has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.85 -$22.73M -$0.89 N/A Interparfums $1.49B 2.19 $168.39M $5.27 19.31

Is VERU or IPAR more profitable?

Interparfums has a net margin of 11.32% compared to Veru's net margin of 0.00%. Interparfums' return on equity of 15.47% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -54.72% -39.09% Interparfums 11.32% 15.47% 10.82%

Does the media favor VERU or IPAR?

In the previous week, Interparfums had 1 more articles in the media than Veru. MarketBeat recorded 4 mentions for Interparfums and 3 mentions for Veru. Interparfums' average media sentiment score of 0.77 beat Veru's score of 0.43 indicating that Interparfums is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Interparfums 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PBH or VERU?

In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than Veru. MarketBeat recorded 8 mentions for Prestige Consumer Healthcare and 3 mentions for Veru. Prestige Consumer Healthcare's average media sentiment score of 0.57 beat Veru's score of 0.43 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prestige Consumer Healthcare 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, HLF or VERU?

Herbalife has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Herbalife $5.04B 0.25 $228.30M $2.28 5.31 Veru $16.89M 2.85 -$22.73M -$0.89 N/A

Is HLF or VERU more profitable?

Herbalife has a net margin of 4.67% compared to Veru's net margin of 0.00%. Herbalife's return on equity of -41.47% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Herbalife 4.67% -41.47% 8.24% Veru N/A -54.72% -39.09%

Veru (VERU) Competitors

$3.00 -0.26 (-7.98%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.02 +0.02 (+0.53%)

As of 06/12/2026 07:58 PM Eastern

Compare

VERU vs. MED, EL, IPAR, PBH, and HLF

Should you buy Veru stock or one of its competitors? MarketBeat compares Veru with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veru include Medifast (MED), Estee Lauder Companies (EL), Interparfums (IPAR), Prestige Consumer Healthcare (PBH), and Herbalife (HLF). These companies are all part of the "personal products" industry.

How does Veru compare to Medifast?

Medifast (NYSE:MED) and Veru (NASDAQ:VERU) are both small-cap personal products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

In the previous week, Medifast and Medifast both had 3 articles in the media. Veru's average media sentiment score of 0.43 beat Medifast's score of 0.22 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.5% of Medifast shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 3.7% of Medifast shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Medifast has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Veru has a beta of -1.14, indicating that its stock price is 214% less volatile than the broader market.

Veru has a net margin of 0.00% compared to Medifast's net margin of -5.78%. Medifast's return on equity of -4.80% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Veru	N/A	-54.72%	-39.09%

Medifast currently has a consensus price target of $12.00, suggesting a potential upside of 1.15%. Veru has a consensus price target of $23.00, suggesting a potential upside of 666.67%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Medifast has higher revenue and earnings than Veru. Medifast is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.34	-$18.67M	-$1.83	N/A
Veru	$16.89M	2.85	-$22.73M	-$0.89	N/A

Summary

Veru beats Medifast on 9 of the 15 factors compared between the two stocks.

How does Veru compare to Estee Lauder Companies?

Veru (NASDAQ:VERU) and Estee Lauder Companies (NYSE:EL) are both personal products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

47.2% of Veru shares are held by institutional investors. Comparatively, 55.2% of Estee Lauder Companies shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 13.1% of Estee Lauder Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Veru has a net margin of 0.00% compared to Estee Lauder Companies' net margin of -1.67%. Estee Lauder Companies' return on equity of 20.66% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-54.72%	-39.09%
Estee Lauder Companies	-1.67%	20.66%	4.15%

Veru currently has a consensus target price of $23.00, indicating a potential upside of 666.67%. Estee Lauder Companies has a consensus target price of $100.65, indicating a potential upside of 12.29%. Given Veru's higher probable upside, equities research analysts clearly believe Veru is more favorable than Estee Lauder Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Estee Lauder Companies	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.50

Veru has higher earnings, but lower revenue than Estee Lauder Companies. Estee Lauder Companies is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.85	-$22.73M	-$0.89	N/A
Estee Lauder Companies	$14.33B	2.26	-$1.13B	-$0.70	N/A

Veru has a beta of -1.14, meaning that its share price is 214% less volatile than the broader market. Comparatively, Estee Lauder Companies has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

In the previous week, Estee Lauder Companies had 14 more articles in the media than Veru. MarketBeat recorded 17 mentions for Estee Lauder Companies and 3 mentions for Veru. Estee Lauder Companies' average media sentiment score of 1.08 beat Veru's score of 0.43 indicating that Estee Lauder Companies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estee Lauder Companies	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Estee Lauder Companies beats Veru on 10 of the 16 factors compared between the two stocks.

How does Veru compare to Interparfums?

Veru (NASDAQ:VERU) and Interparfums (NASDAQ:IPAR) are both personal products companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Veru currently has a consensus price target of $23.00, indicating a potential upside of 666.67%. Interparfums has a consensus price target of $106.00, indicating a potential upside of 4.15%. Given Veru's higher probable upside, equities analysts plainly believe Veru is more favorable than Interparfums.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Interparfums	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Interparfums has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.85	-$22.73M	-$0.89	N/A
Interparfums	$1.49B	2.19	$168.39M	$5.27	19.31

Interparfums has a net margin of 11.32% compared to Veru's net margin of 0.00%. Interparfums' return on equity of 15.47% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-54.72%	-39.09%
Interparfums	11.32%	15.47%	10.82%

Veru has a beta of -1.14, indicating that its share price is 214% less volatile than the broader market. Comparatively, Interparfums has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

47.2% of Veru shares are held by institutional investors. Comparatively, 55.6% of Interparfums shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 43.7% of Interparfums shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Interparfums had 1 more articles in the media than Veru. MarketBeat recorded 4 mentions for Interparfums and 3 mentions for Veru. Interparfums' average media sentiment score of 0.77 beat Veru's score of 0.43 indicating that Interparfums is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Interparfums	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Interparfums beats Veru on 15 of the 17 factors compared between the two stocks.

How does Veru compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Veru (NASDAQ:VERU) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Prestige Consumer Healthcare has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.08	$190.30M	$3.91	12.24
Veru	$16.89M	2.85	-$22.73M	-$0.89	N/A

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 1.4% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Prestige Consumer Healthcare has a net margin of 17.48% compared to Veru's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.54% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	17.48%	11.54%	6.16%
Veru	N/A	-54.72%	-39.09%

Prestige Consumer Healthcare has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Veru has a beta of -1.14, suggesting that its stock price is 214% less volatile than the broader market.

Prestige Consumer Healthcare currently has a consensus price target of $70.75, indicating a potential upside of 47.80%. Veru has a consensus price target of $23.00, indicating a potential upside of 666.67%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than Veru. MarketBeat recorded 8 mentions for Prestige Consumer Healthcare and 3 mentions for Veru. Prestige Consumer Healthcare's average media sentiment score of 0.57 beat Veru's score of 0.43 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Prestige Consumer Healthcare beats Veru on 11 of the 16 factors compared between the two stocks.

How does Veru compare to Herbalife?

Herbalife (NYSE:HLF) and Veru (NASDAQ:VERU) are both small-cap personal products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Herbalife has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Veru has a beta of -1.14, meaning that its share price is 214% less volatile than the broader market.

Herbalife has a net margin of 4.67% compared to Veru's net margin of 0.00%. Herbalife's return on equity of -41.47% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Herbalife	4.67%	-41.47%	8.24%
Veru	N/A	-54.72%	-39.09%

47.2% of Veru shares are held by institutional investors. 5.1% of Herbalife shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Herbalife currently has a consensus target price of $17.80, indicating a potential upside of 46.96%. Veru has a consensus target price of $23.00, indicating a potential upside of 666.67%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Herbalife.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Herbalife	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Herbalife has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Herbalife	$5.04B	0.25	$228.30M	$2.28	5.31
Veru	$16.89M	2.85	-$22.73M	-$0.89	N/A

In the previous week, Veru had 3 more articles in the media than Herbalife. MarketBeat recorded 3 mentions for Veru and 0 mentions for Herbalife. Herbalife's average media sentiment score of 1.88 beat Veru's score of 0.43 indicating that Herbalife is being referred to more favorably in the media.

Company	Overall Sentiment
Herbalife	Very Positive
Veru	Neutral

Summary

Herbalife beats Veru on 9 of the 15 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.32M	$8.47B	$6.75B	$12.02B
Dividend Yield	N/A	2.51%	2.66%	5.61%
P/E Ratio	-3.37	15.64	23.82	24.42
Price / Sales	2.85	7.06	510.69	109.73
Price / Cash	N/A	17.28	44.01	55.64
Price / Book	2.40	3.54	10.66	6.79
Net Income	-$22.73M	$225.32M	$3.57B	$337.66M
7 Day Performance	-11.76%	-1.30%	0.87%	2.56%
1 Month Performance	32.74%	1.92%	0.18%	2.03%
1 Year Performance	-50.91%	-0.87%	25.23%	30.31%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	2.9829 of 5 stars	$3.00 -8.0%	$23.00 +666.7%	-54.1%	$52.32M	$16.89M	N/A	230
MED Medifast	1.4153 of 5 stars	$12.68 +1.2%	$12.00 -5.4%	-9.9%	$139.32M	$385.79M	N/A	870	News Coverage
EL Estee Lauder Companies	4.5663 of 5 stars	$85.76 -3.6%	$101.63 +18.5%	+28.1%	$32.18B	$14.83B	N/A	57,000	Positive News Analyst Forecast
IPAR Interparfums	3.7188 of 5 stars	$92.40 -2.1%	$106.00 +14.7%	-28.1%	$3.02B	$1.49B	17.53	530
PBH Prestige Consumer Healthcare	4.4173 of 5 stars	$45.88 -3.5%	$70.75 +54.2%	-43.7%	$2.25B	$1.09B	11.73	540

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors